Carisma Therapeutics (CARM) - 2024 Q1 - Quarterly Report

See accompanying notes to unaudited interim consolidated financial statements. CARISMA THERAPEUTICS INC. Notes to the Interim Consolidated Financial Statements In late March 2024, the Company and its board of directors approved a revised operating plan to reduce monthly operating expenses and conserve cash to begin implementation in April 2024. The plan, includes several measures such as, including prioritizing CT0525, the Company's second product, as its lead anti-human epidermal growth factor receptor 2 ( ...